Alpha Thalassemia Treatment Market By Type Of Drugs (Folic Acid, Deferasirox, Deferiprone, Hydroxyurea) - Growth, Future Prospects And Competitive Landscape, 2019 – 2027

Industry Outlook

Alpha thalassemia treatment market accounted for a market value of US$ 526.1 Mn in 2018 and projected to grow at a CAGR of 7.1% during the forecast period from 2019 to 2027. Alpha thalassemia is a congenital autosomal recessive disorder caused due to absence or reduction in alpha globin peptides due to a deletion or mutation of the alpha globin genes. Alpha thalassemia usually found in Africa, the Middle East, India, Southeast Asia, southern China, and the Mediterranean region. The key factors responsible for growth of alpha thalassemia treatment market are the rising awareness associated with thalassemia in medical practitioners & public, and support provided by government & non-government organizations to manage and treat thalassemia.

Market Synopsis

Alpha Thalassemia Treatment Market

Get a sample copy for more information

"Deferasirox being the only approved drug for alpha thalassemia treatment will dominate the market throughout the forecast period"

In 2018, deferasirox will dominate the market throughout the forecast period as it is the only approved drug therapy by USFDA for alpha thalassemia. According to market experts, deferasirox possess efficient oral bioavailability and a long half-life appropriate for once-daily dosing. Overall, deferasirox is similar to deferoxamine in reducing liver iron and serum ferritin levels in a dose-dependent style. It is use widely across the world for alpha thalassemia treatment because its once-per-day oral dosage. However, Darbepoetin Alfa is present in phase III of clinical trials and expected to get approval very soon but there are a few drawbacks observed in the Phase IIa that might have some effect on its approval. If it gets approved it will be observed as the fastest growing drug in this market.

Alpha Thalassemia Treatment Market

Get a sample copy for more information

"Increasing awareness related to the treatment & management of alpha thalassemia in Asia Pacific makes it the fastest growing region throughout the forecast period"

The Asia Pacific will grow gradually throughout the forecast period from 2018 to 2026, the key factors responsible for growth of alpha thalassemia treatment market in this region are rising awareness related to alpha thalassemia treatment & management and increasing support provided by governmental & non-governmental organizations to develop awareness in public. According to market experts, alpha-thalassemia is specifically common among Southeast Asian population descent 1-30% of the population has a thalassemia trait; up to 40% may be a genetic carrier.

Alpha Thalassemia Treatment Market

Alpha Thalassemia Treatment Market

Get a sample copy for more information

Historical & Forecast Period

The alpha thalassemia treatment market analyzed considering current market trends for base year 2018 and based on future trends CAGRs calculated for the forecast period from 2019 to 2027.

Report Scope by Segments

This report provides detailed research study related to alpha thalassemia treatment market covering market interpretations and assumptions included based on brief qualitative and quantitative data research carried out through primary and secondary research. Industry experts have value-added and assisted to analyze market dynamics such as drivers, opportunities & challenges further segmented to region-level & country-level. This report also comprises comprehensive analysis of global alpha thalassemia treatment market segmented as types of drug, and geography. The report also gives data related to competitive landscape of the major companies present and operate in alpha thalassemia treatment market that covers detailed information including company information such as latest business strategies, financial data, & product profiles.

ATTRIBUTE DETAILS
Research Period  2017-2027
Base Year 2018
Forecast Period  2019-2027
Historical Year  2017
Unit  USD Million
Segmentation

 Type of Drug (2017–2027; US$ Mn)
 • Folic Acid
 • Deferasirox
 • Deferiprone
 • Hydroxyurea

 Pipeline Analysis
 • Darbepoetin Alfa (Phase III)
 • Enriched Hematopoetic Stem Cell Infusion (Phase II)
 • In utero hematopoietic stem cell transplantation (Phase I)

 Geography Segment (2017–2027; US$ Mn)
 • North America (U.S., Canada)
 • Europe (U.K., Germany, Rest of Europe)
 • Asia Pacific (Japan, China, Rest of APAC)
 • Latin America (Brazil, Mexico, Rest of LATAM)
 • Middle East and Africa (GCC, Rest of MEA)

The key companies present in the market analyzed & presented based on product portfolio, current market updates, financial information, and key strategies. This report also covers attractive investment proposition evaluated with the help of PESTEL analysis, which based on detailed geographical research. Major companies studied in the overall report are GlaxoSmithKline, Novartis AG, Bellicum Pharmaceuticals, Acceleron Pharma, Johnson & Johnson, Merck & Co., and Gilead Sciences, Inc. among others.

Key questions answered in this report

  • Which is the trending drug type in the market preferred for alpha thalassemia treatment & Why?
  • What are the current market strategies & policies planned & applied by key companies & competitive landscape of the alpha thalassemia treatment market?
  • Which are the important & potential geographical markets (regions and countries) in alpha thalassemia treatment market?
  • Which is the largest and fastest growing region globally?
Choose License Type
Published Date:  Jun 2019
Category:  Pharmaceuticals
Report ID:   59721
Report Format:   PDF
Pages:   120
Rating:    4.2 (56)
Connect With Us
+1-408-641-3282
24/7 Research Support